Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
In 2018, the global Immune Thrombocytopenia Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Immune Thrombocytopenia Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immune Thrombocytopenia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.
...

Market segment by Type, the product can be split into
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs

Market segment by Application, split into
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Immune Thrombocytopenia Drugs status, future forecast, growth opportunity, key market and key players.
To present the Immune Thrombocytopenia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Immune Thrombocytopenia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.